BINDING OF THE MUSCARINE RECEPTOR ANTAGONIST HEPTANE-1,7-BIS(DIMETHYL-3'-PHTHALIMIDOPROPYL)AMMONIUM BROMIDE AT CHOLINOCEPTOR SITES

被引:18
作者
CHRISTOPOULOS, A
LOIACONO, R
MITCHELSON, F
机构
[1] MONASH UNIV, VICTORIAN COLL PHARM, SCH PHARMACOL, 381 ROYAL PARADE, PARKVILLE, VIC 3052, AUSTRALIA
[2] MONASH UNIV, DEPT PHARMACOL, CLAYTON, VIC 3168, AUSTRALIA
来源
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 1993年 / 246卷 / 01期
关键词
MUSCARINE RECEPTOR ANTAGONIST; CEREBRAL CORTEX; CHOLINOCEPTOR;
D O I
10.1016/0922-4106(93)90002-Q
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The binding of the bisquaternary muscarine receptor antagonist heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)-ammonium bromide (C-7/3-phth) was investigated at a number of cholinergic binding sites using (-)-[H-3]nicotine, [H-3]pirenzepine and (-)-[H-3]quinuclidinyl benzilate ([H-3]QNB) in both central and peripheral tissues. C-7/3-phth displayed an affinity for muscarine M2 receptors in rat atria (70.1 nM) which was 1.6-fold greater than for putative M4 receptors in rabbit lung, and 4- to 5-fold greater than for M1 receptors in rat cerebral cortex. Its affinity for nicotine receptors in the cortex was low, being 808-fold lower than its affinity for the M2 receptor. Although the displacement of (-)-[H-3]nicotine and [H-3]pirenzepine binding in rat cortex by C-7/3-phth was best described in terms of one-site modelling, low Hill coefficients were observed with C-7/3-phth in displacement studies using [H-3]QNB in this tissue. The possibility of allosteric interactions or multiple receptor subtype interactions is discussed.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 40 条
[1]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[2]  
CASTOLDI AF, 1991, RES COMMUN CHEM PATH, V74, P371
[3]   CHARACTERIZATION OF THE ANTIMUSCARINIC EFFECT OF HEPTANE-1,7-BIS-(DIMETHYL-3'-PHTHALIMIDOPROPYL AMMONIUM BROMIDE) [J].
CHOO, LK ;
MITCHELSON, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (03) :429-435
[4]   SELECTIVE-INHIBITION OF RESPONSES TO CARBACHOL AND MCN-A-343 IN THE RABBIT VAS-DEFERENS [J].
CHOO, LK ;
MITCHELSON, F .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1990, 17 (09) :601-611
[5]  
CHOO LK, 1983, CAN J PHYSL PHARM, V63, P200
[6]  
DELEAN A, 1982, MOL PHARMACOL, V21, P5
[7]  
DORJE F, 1991, J PHARMACOL EXP THER, V256, P727
[8]  
DORJE F, 1991, MOL PHARMACOL, V40, P459
[9]  
EHLERT FJ, 1990, J PHARMACOL EXP THER, V255, P1148
[10]  
GILANI SAH, 1986, N-S ARCH PHARMACOL, V332, P16